--- title: "Innocore Signs New Long-Acting Injectable Formulation Contract with Returning Top 10 Global Pharma Partner" id: "1783" type: "post" slug: "innocore-pharmaceuticals-signs-new-long-acting-injectable-formulation-contract-with-returning-top-10-global-pharma-partner" published_at: "2025-09-11T12:26:36+00:00" modified_at: "2026-04-17T13:27:20+00:00" url: "https://innocorepharma.com/news-events/innocore-pharmaceuticals-signs-new-long-acting-injectable-formulation-contract-with-returning-top-10-global-pharma-partner/" markdown_url: "https://innocorepharma.com/news-events/innocore-pharmaceuticals-signs-new-long-acting-injectable-formulation-contract-with-returning-top-10-global-pharma-partner.md" taxonomy_category: - "Latest News" --- 11 September 2025 | Latest News # Innocore Signs New Long-Acting Injectable Formulation Contract with Returning Top 10 Global Pharma Partner # **Innocore Signs New Long-Acting Injectable Formulation Contract with Returning Top 10 Global Pharma Partner** - ***New project underscores Innocore’s growing role as a trusted, long-term collaborator for complex peptide and biologic drug delivery*** **Groningen, The Netherlands – 11 September 2025** – InnoCore Pharmaceuticals (“InnoCore”), a leading specialist in long-acting injectable (LAI) drug delivery technologies, today announced a new formulation development contract with a returning Top 10 global pharmaceutical company. The new agreement builds on the success of earlier collaborations and further strengthens the long-standing relationship between the two companies. The project will again leverage InnoCore’s proprietary SynBiosys® technology, a best-in-class biodegradable polymer platform designed to address the complex challenges of formulating peptide and biologic APIs into scalable, stable, and tunable LAI dosage forms. Martin Bakker, CBO at InnoCore Pharmaceuticals, said: *“We have extended our partnership again**with one of the world’s largest pharmaceutical companies which is important validation of our reputation in the biologics and peptide formulation space. This repeat collaboration highlights the confidence our partners place in both our scientific expertise and the proven capabilities of our SynBiosys® platform. It also underscores the client’s positive perception of the strategic value that our technology can bring. We are looking forward to working again with this customer team.”* The new agreement also marks another milestone in InnoCore’s strategic expansion within the biologics and peptide formulation market, reflecting the Company’s growing reputation as a partner of choice for both large pharmaceutical and innovative biotech organizations seeking advanced, patient-centric sustained-release solutions. With over 20 years of experience in formulation and process development, InnoCore combines deep scientific know-how with state-of-the-art polymer synthesis, analytical characterization, and scale-up facilities in Groningen, The Netherlands. The Company’s multidisciplinary team specializes in translating complex APIs into robust LAI dosage forms designed for both clinical and commercial manufacture. This new collaboration adds to InnoCore’s growing portfolio of global partnerships and reinforces its commitment to innovation, reliability, and excellence in advanced drug delivery systems. -Ends- **For more information, please contact:** | InnoCore Pharmaceuticals | Contact details | | --- | --- | | Martin Bakker, CBO | [email protected] Tel: +31 50 575 3100 | | Vigo Consulting | | | Melanie Toyne-Sewell Rozi Morris | [email protected] Tel: +44 7390 0230 | **Notes to Editors** **About InnoCore Pharmaceuticals** InnoCore Pharmaceuticals is a leading drug delivery development provider, formulating peptide and biologic APIs into scalable, biodegradable and tunable Long Acting Injectable (LAI) dosage forms. The Company’s proprietary polymeric drug delivery platform, SynBiosys®, overcomes the significant technical challenges of translating these complex and fragile molecules into LAI drug products that maintain their essential bioactive characteristics. Dosage forms can be created for early proof of concept, through to clinical trial usage in an easy-to-scale cGMP form. These formulations can be adapted for use in local or systematic injectable forms for a wide range of therapeutic applications, such as osteoarthritis, rheumatology, oncology, CNS, infectious and cardiometabolic diseases. InnoCore is a true strategic partner to its biopharma customers working hand-in-hand with them to lay strong foundations for future clinical and commercial success. InnoCore is innovating biologic drug formulation for better treatment outcomes and compliance. For more information, please see: [www.innocorepharma.com](http://www.innocorepharma.com) . Related insights [26 July 2018 | Funding InnoCore and Merck enter global collaboration Merck and InnoCore Pharmaceuticals to Improve Patient Compliance with New Drug Delivery Technology. Read the full story](https://innocorepharma.com/news-events/innocore-and-merck-enter-global-collaboration/) [11 September 2020 | Funding Bill & Melinda Gates Foundation Grant Awarded InnoCore Pharmaceuticals has been awarded a grant by the Bill & Melinda Gates Foundation to develop a long-acting injectable contraceptive implant. Read the full story](https://innocorepharma.com/news-events/innocore-awarded-grant-by-the-bill-melinda-gates-foundation-in-contraception/) [01 January 2021 | Funding InnoCore leads Consortium in Influenza vaccines InnoCore Pharmaceuticals has secured funding from the European Regional Development Fund to develop a biodegradable polymer-based microneedle array patch. Read the full story](https://innocorepharma.com/news-events/innocore-leads-consortium-in-influenza-vaccines/)